Combination of ertugliflozin, sitagliptin proven superior

The co-administration of ertugliflozin and sitagliptin was significantly more effective than either therapy alone in reducing HbA1c and fasting plasma glucose in patients with type 2 diabetes who were already on metformin therapy, according to results from the VERTIS Factorial trial presented at the American Diabetes Association Scientific Sessions.

The combination therapy was also more effective in reducing body weight and systolic blood pressure compared with sitagliptin alone. Pratley and colleagues conducted a double blind, phase 3 trial and randomized 1,233 patients with an HbA1c between 7.5% and 11% on stable metformin ≥ 1,500 mg/day to one of five treatment groups.

HbA1c levels were reduced below 7% in 52.3% of patients who received combination therapy with ertugliflozin 5 mg and in 49.2% of patients receiving combination therapy with ertugliflozin 15 mg at the end of the 26-week trial (P < .001 for both).

Reference:
Pratley R, et al. 125-LB. Presented at: American Diabetes Association’s Scientific Sessions; June 10-14, 2016; New Orleans.